A look into the 340B explosion of growth as Gilead and J&J join more than a dozen peers setting their own terms

As a new report documents the explosive growth of a federal program providing discounted drugs for low-income Americans, two more large pharma companies — Gilead and Johnson & Johnson — will place new restrictions around their policies for the program, known as 340B. Including Gilead and J&J, a total of…

...

Click to view original post